Nektar Therapeutics (NKTR) CEO sells 423 shares in non-discretionary tax sale

Rhea-AI Filing Summary

Nektar Therapeutics President & CEO Robin Howard W reported an open-market sale of 423 shares of common stock on February 18, 2026 at a weighted average price of $73.00 per share. According to the disclosure, these shares were sold to cover required tax withholding obligations related to vesting restricted stock units, and the filing notes this was not a discretionary trade. After the transaction, he directly held 75,489 shares of common stock, with an additional 28 shares held indirectly by his spouse.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBIN HOWARD W

(Last) (First) (Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO CA 94158

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		S		423(1)	D	$73(2)	75,489	D
Common Stock								28	I	by spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $72.51 to $74.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

	Elizabeth Zhang, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nektar Therapeutics (NKTR) report for Robin Howard W?

Nektar Therapeutics reported that President & CEO Robin Howard W sold 423 shares of common stock. The sale occurred on February 18, 2026, at a weighted average price of $73.00 per share, in connection with tax withholding on vesting RSUs.

Was the NKTR CEO’s February 18, 2026 stock sale a discretionary trade?

No, the filing states the 423 shares were sold to cover required tax withholding obligations from vesting RSUs and “does not represent a discretionary trade.” This characterizes the sale as administrative rather than an elective open-market reduction in holdings.

What price range applied to the Nektar Therapeutics CEO’s reported share sale?

The transaction was executed in multiple trades at prices ranging from $72.51 to $74.00. The reported $73.00 per-share figure is the weighted average sale price across those individual trades, as disclosed in the filing footnote.

How many Nektar Therapeutics shares does Robin Howard W hold after this Form 4?

Following the reported sale, Robin Howard W directly held 75,489 shares of Nektar Therapeutics common stock. The filing also shows an additional 28 shares held indirectly, reported as owned by his spouse, reflecting his total reported positions.

What does the indirect ownership by spouse mean in the NKTR Form 4?

The Form 4 lists 28 shares of Nektar Therapeutics common stock as indirectly owned “by spouse.” This indicates those shares are held in the spouse’s name, with the position reported as indirect beneficial ownership associated with the insider.

How many shares did the Nektar Therapeutics CEO sell, and what is the net effect?

He sold 423 shares of common stock, all tied to tax withholding on RSU vesting. After this non-discretionary sale, his direct holdings stand at 75,489 shares, plus 28 shares indirectly owned through his spouse, according to the disclosure.